Evidence map›Paper›PMID 41975207›Full record

SynthesisJournal of perinatology : official journal of the California Perinatal Association2026

The impact of maternal respiratory syncytial virus vaccination on infant and perinatal outcomes: a systematic review and meta-analysis of randomized controlled trials.

Jonathan Rodrigues Lopes, Inês Martins Esteves, Sofia Oliveira Dias, Fátima Maria Thaiz da Fonte Gomes da Silva, Gabrielle Catherine Dias Mafra da Silva, Natália Botelho Libonati, Regina Melittio Gasparetti, Angelica Luciana Nau

Abstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Journal of perinatology : official journal of the California Perinatal Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jonathan Rodrigues LopesFaculdade de Ciências Médicas de São José dos Campos HUMANITAS, São José dos Campos, Brazil. jonathanlopes.med@gmail.com.ORCID http://orcid.org/0009-0002-7300-0178
Inês Martins EstevesSchool of Medicine and Biomedical Sciences, University of Porto, Porto, Portugal.ORCID http://orcid.org/0000-0002-8867-7424
Sofia Oliveira DiasFaculdade de Ciências Médicas de São José dos Campos HUMANITAS, São José dos Campos, Brazil.ORCID http://orcid.org/0009-0001-9509-3144
Fátima Maria Thaiz da Fonte Gomes da SilvaFederal University of Paraíba, João Pessoa, Brazil.
Gabrielle Catherine Dias Mafra da SilvaFaculdade de Ciências Médicas de São José dos Campos HUMANITAS, São José dos Campos, Brazil.
Natália Botelho LibonatiPontifical Catholic University of Minas Gerais, Belo Horizonte, Brazil.
Regina Melittio GasparettiFaculdade de Ciências Médicas de São José dos Campos HUMANITAS, São José dos Campos, Brazil.
Angelica Luciana NauFederal University of Santa Catarina, Florianópolis, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo assess the efficacy and safety of maternal respiratory syncytial virus (RSV) vaccination on infant and perinatal outcomes. STUDY

designSystematic review and random-effects meta-analysis of randomized controlled trials (PubMed, Embase, CENTRAL). Six trials (18,011 pregnant women; 17,769 infants) comparing maternal RSV vaccines with placebo were included. Effects were pooled as risk ratios (RR).

resultsMaternal RSV vaccination reduced severe RSV-associated lower respiratory tract infection (LRTI) (RR 0.35, 95% CI 0.15-0.87) and hospitalization (RR 0.53, 95% CI 0.37-0.76) within 180 days of birth. Medically attended RSV-LRTI was lower but imprecise (RR 0.47, 95% CI 0.18-1.21). No safety signal was observed for preterm birth (RR 1.15, 95% CI 0.95-1.38), low birth weight, or congenital malformations.

conclusionMaternal RSV vaccination reduces severe infant RSV disease and RSV-related hospitalization with a reassuring perinatal safety profile.

trial registrationPROSPERO CRD42025636472.

Indexed as

Pregnancy Complications, InfectiousRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesRespiratory Tract InfectionsFemaleHospitalizationHumansInfantInfant, NewbornPregnancyPregnancy OutcomeRandomized Controlled Trials as TopicVaccinationRespiratory Syncytial Virus Vaccines

Identifiers

PMID41975207

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.